| Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449) |
|---|
| 02/03/2005 | US20050026893 Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants |
| 02/03/2005 | US20050026888 Formulation containing anti-inflammatory androstane derivatives |
| 02/03/2005 | US20050026877 Pharmaceutical compositions comprising active vitamin D compounds |
| 02/03/2005 | US20050026844 Inhibitors for the soluble epoxide hydrolase |
| 02/03/2005 | US20050026828 Methods for modulating gastric secretion using prokineticin receptor antagonists |
| 02/03/2005 | US20050026298 Dye solutions for use in methods to detect the prior evaporation of anhydrous ammonia and the production of illicit drugs |
| 02/03/2005 | US20050026192 Oligonucleotide synthesis with alternative solvents |
| 02/03/2005 | US20050025847 For preventing sexually transmitted disease (STD) infections which includes bisabolol; STDs such as HIV, herpes, gonorrhea, chlamydia, syphilis, and trichomoniasis |
| 02/03/2005 | US20050025820 Method and system for systemic delivery of growth arresting, lipid-derived bioactive compounds |
| 02/03/2005 | US20050025779 Immunogenic gp120 polypeptides and polynucleotides; expression vectors and host cells; medical diagnosis; vaccines |
| 02/03/2005 | US20050025771 Antitumor agents comprising a targeting portion and an immune response triggering portion |
| 02/03/2005 | US20050025763 Therapeutic use of anti-CS1 antibodies |
| 02/03/2005 | US20050025753 Methods for production of non-disease causing hemoglobin by ex vivo oligonucleotide gene editing of human stem/progenitor cells |
| 02/03/2005 | US20050025742 Interferon or a gene delivery system encoding the interferon and SYN3 as delivery enhancing agent; protein or gene therapy; transurethral intravesical administration to epithelial cells; superficial bladder cancer |
| 02/03/2005 | US20050025711 Contrast media formulations having improved biological tolerance |
| 02/03/2005 | US20050022812 Low dose pharmaceutical powders for inhalation |
| 02/03/2005 | CA2783275A1 Stable radiopharmaceutical compositions and methods for their preparation |
| 02/03/2005 | CA2534989A1 Stable aluminum/zirconium antiperspirant solution |
| 02/03/2005 | CA2533649A1 Combined treatments comprising synthetic peptide copolymers for preventing graft rejection |
| 02/03/2005 | CA2533592A1 Controlled release compositions |
| 02/03/2005 | CA2533588A1 Immediate-release formulation of acid-labile pharmaceutical compositions |
| 02/03/2005 | CA2533577A1 Orally dissolving films |
| 02/03/2005 | CA2533418A1 Method and device for regulation of limbic system of the brain by means of neuro-electrical coded signals |
| 02/03/2005 | CA2533151A1 Pharmaceutical formulations |
| 02/03/2005 | CA2532926A1 Combined use of immunostimulatory oligonucleotides and cytokines or radiation |
| 02/03/2005 | CA2532922A1 Composition and method for treating neurological disorders |
| 02/03/2005 | CA2532874A1 Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof |
| 02/03/2005 | CA2532802A1 Antibiotic compound isolated from streptomyces sp |
| 02/03/2005 | CA2532800A1 Anaplastic lymphoma kinase modulators and methods of use |
| 02/03/2005 | CA2532798A1 Azepine derivatives as pharmaceutical agents |
| 02/03/2005 | CA2532443A1 Tyrosine kinase inhibitors |
| 02/03/2005 | CA2532433A1 Muscarinic acetylcholine receptor antagonists |
| 02/03/2005 | CA2532430A1 Humanized versions of monoclonal antibody ds6 that bind tumour antigen ca6 |
| 02/03/2005 | CA2532370A1 Polypeptides for inducing a protective immune response against staphylococcus aureus |
| 02/03/2005 | CA2532360A1 Compositions related to a novel endophytic fungi and methods of use |
| 02/03/2005 | CA2532302A1 Method for the preparation of controlled release formulations |
| 02/03/2005 | CA2532035A1 Fugetactic proteins, compositions and methods of use |
| 02/03/2005 | CA2531637A1 Cellulosic fiber containing composition |
| 02/03/2005 | CA2525829A1 Method of inhibiting atf/creb and cancer cell growth and pharmaceutical compositions for same |
| 02/03/2005 | CA2517600A1 Methods and compositions for the treatment and prevention of staphylococcus and other bacterial infections |
| 02/03/2005 | CA2517260A1 Tetracyclic benzamide derivatives and methods of use thereof |
| 02/03/2005 | CA2516783A1 Human lymphocyte vaccine adjuvant |
| 02/02/2005 | EP1502602A2 Methods for therapeutic vaccination |
| 02/02/2005 | EP1502592A1 Controlled release oxycodone compositions |
| 02/02/2005 | EP1501895A1 Compositions comprising anionic functionalized polyorganosiloxanes for hydrophobically modifying surfaces and enhancing delivery of active agents to surfaces treated therewith |
| 02/02/2005 | EP1501482A1 Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease |
| 02/02/2005 | EP1501452A2 Injectable chondrocyte implant |
| 02/02/2005 | EP1463576A4 Mesoporous permeation layers for use on active electronic matrix devices |
| 02/02/2005 | EP1007017B1 New formulation for inhalation having a poured bulk density of 0.28 to 0.38 g/ml, a process for preparing the formulation and the use thereof |
| 02/02/2005 | CN1575173A Macrolides containing pharmaceutical compositions |
| 02/02/2005 | CN1572792A Pyrazolo [4, 3-d] pyrimidine derivatives |
| 02/02/2005 | CN1187369C Method for producing peptide salts. their use, and pharmaceutical prepns. containing these peptide salts |
| 02/02/2005 | CN1187351C Bispidine compounds, their use and preparation method, intermediate and pharmaceutical compositions containing same |
| 02/02/2005 | CN1187350C Bispidine compounds, their use and preparation method, intermediate and pharmaceutical compositions containing same |
| 02/02/2005 | CN1187318C Solid composition suitable for oral administration comprising non hydroscopic salts of L-carnitine or alkanoyl-L-carnitine with 2-aminoethanesulfonic acid |
| 02/02/2005 | CN1187060C Extracts of shark cartilage, its preparation method and usage |
| 02/02/2005 | CN1187044C Storable active substance concentrate containing formoterol |
| 02/02/2005 | CN1186979C Retarding formulations of plant protectant |
| 02/01/2005 | US6849737 Synthesis and purification of valacyclovir |
| 02/01/2005 | US6849120 Oxidizing 2-((diphenylmethyl)thio)acetamide with hydrogen peroxide in mixture of mineral acid with alcohol or phase transfer catalyst, precipitating solid, and separating |
| 01/27/2005 | WO2005007628A1 Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
| 01/27/2005 | WO2005007124A2 Substituted dihydropyrimidine inhibitors of calcium channel function |
| 01/27/2005 | WO2005007123A2 Pin1-modulating compounds and methods of use thereof |
| 01/27/2005 | WO2005007122A2 Polymer stabilization |
| 01/27/2005 | WO2005007121A2 Mutant interleukin-2(il-2) polypeptides |
| 01/27/2005 | WO2005007120A2 System and method for treating nausea and vomiting by vagus nerve stimulation |
| 01/27/2005 | WO2005007118A2 Treatment or prevention of damage due to radiation exposure |
| 01/27/2005 | WO2005007117A2 Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders |
| 01/27/2005 | WO2005007116A2 Artificial antigen presenting cell devices |
| 01/27/2005 | WO2005007115A2 Pharmaceutical composition for inhibiting acid secretion |
| 01/27/2005 | WO2005007114A2 Method of treating diabetes type ii |
| 01/27/2005 | WO2005007113A2 Appetite control compositions and methods of use |
| 01/27/2005 | WO2005007112A2 Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration |
| 01/27/2005 | WO2005007111A2 Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
| 01/27/2005 | WO2005007110A2 Compositions and methods for hydrophobic drug delivery |
| 01/27/2005 | WO2005007109A2 Methods and compositions for cancer therapy using a novel adenovirus |
| 01/27/2005 | WO2005007108A2 Asymmetric disulfides and methods of using same |
| 01/27/2005 | WO2005007107A2 Histamine and cck2/gastrin receptor blockade in the treatment of acid-peptic disease and cancer |
| 01/27/2005 | WO2005007106A2 Compositions of a cyclooxygenase-2 selective inhibitor and a non-nmda glutamate modulator for the treatment of central nervous system damage |
| 01/27/2005 | WO2005007105A2 Pharmaceutical compositions |
| 01/27/2005 | WO2005007104A2 Novel compositions, pharmaceutical compositions, and methods for the treatment and prevention of heart disease |
| 01/27/2005 | WO2005007103A2 Use of parthenolide derivatives as antileukemic and cytotoxic agents |
| 01/27/2005 | WO2005007102A2 Phytochemicals for the treatment of mastalgia, endometriosis and hpv-related conditions including cervical dysplasia |
| 01/27/2005 | WO2005007101A2 Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium |
| 01/27/2005 | WO2005007100A2 Pharmaceutical compositions for topical application |
| 01/27/2005 | WO2005007099A2 Pkb inhibitors as anti-tumor agents |
| 01/27/2005 | WO2005007098A2 Nucleic acid therapy to enhance cartilage repair |
| 01/27/2005 | WO2005007096A2 Treatment of movement disorders with a metabotropic glutamate 4 receptor positive allosteric modulator |
| 01/27/2005 | WO2005007094A2 Asthma and allergic inflammation modulators |
| 01/27/2005 | WO2005007093A2 Uses of il-12 in hematopoiesis |
| 01/27/2005 | WO2005007092A2 Novel chemical compounds |
| 01/27/2005 | WO2005007091A2 Histone deacetylase inhibitors and methods of use thereof |
| 01/27/2005 | WO2005007090A2 Inhibitors of the map kinase pathway |
| 01/27/2005 | WO2005007088A2 Stabilized anthocyanin extract from garcinia indica |
| 01/27/2005 | WO2005007087A2 Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators |
| 01/27/2005 | WO2005007086A2 A method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture |
| 01/27/2005 | WO2005007085A2 Pyrazolo pyrimidine derivatives and methods of use thereof |
| 01/27/2005 | WO2005007084A2 Pancratistatin cyclic phosphate prodrugs an phenpanstatin cyclic phosphate prodrugs |
| 01/27/2005 | WO2005007083A2 Chemical compounds |
| 01/27/2005 | WO2005007082A2 Treatment of chronic bacterial infection |